The estimated Net Worth of Ivan M Lieberburg is at least $1.13 Milion dollars as of 7 December 2015. Ivan Lieberburg owns over 3,000 units of Adamas Pharmaceuticals Inc stock worth over $394,560 and over the last 10 years he sold ADMS stock worth over $663,150. In addition, he makes $67,705 as Independent Director at Adamas Pharmaceuticals Inc.
Sign up
Ivan Lieberburg ADMS stock SEC Form 4 insiders trading
Ivan has made over 12 trades of the Adamas Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of ADMS stock worth $48,690 on 7 December 2015.
The largest trade he's ever made was selling 3,000 units of Adamas Pharmaceuticals Inc stock on 7 December 2015 worth over $48,690. On average, Ivan trades about 2,000 units every 19 days since 2015. As of 7 December 2015 he still owns at least 48,000 units of Adamas Pharmaceuticals Inc stock.
You can see the complete history of Ivan Lieberburg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ivan Lieberburg biography
Dr. Ivan M. Lieberburg Ph.D. M.D. serves as Independent Director of the Company. Dr. Lieberburg has been a member of the Tavistock Group, a private equity firm, since 2009, and a managing director of Boxer Capital, since 2017, where he concentrates on health care and life sciences investment opportunities. From 1987 to 2009, Dr. Lieberburg was employed by Elan Pharmaceuticals, Inc. (formerly Athena Neurosciences, Inc.), where his most recent roles were as Executive Vice President, Corporate Office of Technology and Chief Medical Officer. Dr. Lieberburg holds an A.B. in Biology from Cornell University, a Ph.D. in Neurobiology from The Rockefeller University, and an M.D. from the University of Miami Leonard M. Miller School of Medicine. Dr. Lieberburg is board certified in internal medicine and endocrinology/metabolism. Lieberburg’s executive experience in the life sciences industry and his medical training qualifies him to serve on our Board of Directors.
What is the salary of Ivan Lieberburg?
As the Independent Director of Adamas Pharmaceuticals Inc, the total compensation of Ivan Lieberburg at Adamas Pharmaceuticals Inc is $67,705. There are 8 executives at Adamas Pharmaceuticals Inc getting paid more, with Neil McFarlane having the highest compensation of $2,080,640.
How old is Ivan Lieberburg?
Ivan Lieberburg is 70, he's been the Independent Director of Adamas Pharmaceuticals Inc since 2004. There are no older and 12 younger executives at Adamas Pharmaceuticals Inc.
What's Ivan Lieberburg's mailing address?
Ivan's mailing address filed with the SEC is C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE, CA, 94608.
Insiders trading at Adamas Pharmaceuticals Inc
Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney a William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.
What does Adamas Pharmaceuticals Inc do?
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
What does Adamas Pharmaceuticals Inc's logo look like?
Complete history of Ivan Lieberburg stock trades at Adamas Pharmaceuticals Inc
Adamas Pharmaceuticals Inc executives and stock owners
Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Neil McFarlane,
Chief Executive Officer, Director -
Vijay Shreedhar,
Chief Commercial Officer -
Christopher Prentiss,
Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer -
David Mahoney,
Lead Independent Chairman of the Board -
Martha Demski,
Independent Director -
William Ericson,
Independent Director -
Michael Bigham,
Independent Director -
Mardi Dier,
Independent Director -
Ivan Lieberburg,
Independent Director -
John MacPhee,
Director -
Anna Richo,
Director -
Adrian Quartel,
Chief Medical Officer -
Adrian Quartel M.D.,
Chief Medical Officer -
Eric C. Schlezinger,
Head of HR -
Dr. Jill M. Jene,
Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management -
Sarah Mathieson,
Head of Corp. Communications, Patient Advocacy & Engagement -
Richard H Booth,
Director -
Rajiv Patni,
Chief Medical Officer -
Ix Lp Seventh Mdv Partners,...,
-
William J Dawson,
Chief Financial Officer -
Natalie Mc Clure,
SVP, Product Development -
Point Partners Llcjay Jeffr...,
-
Richard King,
Chief Operating Officer -
Gregory T Went,
Chief Executive Officer -
Alfred G Merriweather,
Chief Financial Officer -
Jennifer J Rhodes,
General Counsel -
Capital Equity Investments,...,
10% owner -
Sara Grootwassink Lewis,
Director -
Jeffrey H Knapp,
Chief Operating Officer -
Grace Shin,
General Counsel -
Vii Lpmdv Ix Lp Seventh Mdv...,
-
Ventures Management Iii, Ll...,
-
Spyros Papapetropoulos,
Director